Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on brain & cognitive health. Browse all Brain & Cognitive Health education

Dopamine is the brain’s currency of motivation, reward, and reinforcement. A single common variant, rs1800497, influences how efficiently that system works — and researchers have connected it to addictive behaviors, mood regulation, and how strongly the brain responds to reward. Understanding this variant is a window into your own reward biology.

What DRD2 and the rs1800497 Variant Do

The DRD2 gene encodes the dopamine D2 receptor, a key docking site for dopamine in reward and motivation circuits. The variant rs1800497 — historically called the DRD2 Taq1A polymorphism — actually sits in the neighboring ANKK1 gene, but it strongly affects D2 receptor availability. Carriers of the A1 (T) allele tend to have roughly 30 to 40 percent fewer D2 receptors in some brain regions, according to imaging studies. Fewer receptors can mean the reward system is harder to satisfy.

The Reward Deficiency Hypothesis

Because the A1 allele is associated with lower D2 receptor density, scientists proposed the reward deficiency syndrome model: when the brain’s baseline reward signaling is muted, a person may seek stronger or more frequent stimulation to reach the same sense of satisfaction. This framework has been used to study why some people are more vulnerable to compulsive behaviors around food, substances, or other rewarding activities. It is a hypothesis with support, not a verdict on any individual.

rs1800497 and Addictive Behaviors

Meta-analyses have linked the A1 allele of rs1800497 to modestly increased risk for alcohol dependence, nicotine use, and other substance-related behaviors. The associations are real but small — this is a susceptibility factor among many, not a cause. Most carriers never develop an addiction, and many people without the variant do. Environment, stress, early experiences, and access matter enormously alongside genetics.

The same reward biology has been studied in the context of eating behavior. Some research connects lower D2 receptor availability to stronger responses to highly palatable food and to patterns of compulsive overeating, which is why rs1800497 appears in the literature on both substance use and food reward. The common thread is dopamine signaling, not any single behavior — and the practical implication is awareness, not a label, of how your reward system may be tuned.

rs1800497 and Mood

Because dopamine signaling shapes motivation and emotional regulation, rs1800497 has also been studied in relation to mood. Some research associates the A1 allele with differences in stress response, reward-based learning, and vulnerability to low mood, while other studies find weaker effects. The takeaway is that this variant is one thread in the complex biology of mood — not a diagnosis and not a predictor of any condition.

What the Research Shows and Its Limits

Imaging studies consistently tie the A1 allele to lower striatal D2 receptor density, and behavioral genetics studies show reproducible but modest associations with reward sensitivity. Importantly, effect sizes are small and populations differ, so no single result should be read as destiny. Genetic insight is most useful as context for a conversation, not as a label.

What Your Genetic Insights Reveal

The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in dopamine and reward-related pathways such as DRD2 and ANKK1. Seeing your rs1800497 status in context helps you understand tendencies in motivation and reward — information you can bring to a qualified provider. PlexusDx tells you about your biology; it does not diagnose, treat, or manage any mental-health condition.

Frequently Asked Questions

Does rs1800497 mean I will become addicted?

No. The A1 allele of rs1800497 is a modest susceptibility factor, not a cause of addiction. Most carriers never develop a substance problem, and many non-carriers do. Environment, stress, and life experience weigh heavily. Genetics describes a tendency you can understand and act on, not a fixed outcome.

Is rs1800497 in the DRD2 or ANKK1 gene?

The variant sits inside the ANKK1 gene, next to DRD2, but it is historically named the DRD2 Taq1A polymorphism. It affects dopamine D2 receptor availability, which is why it is studied under DRD2 reward biology. Both names refer to the same rs1800497 marker.

Can genetic testing diagnose a mood disorder?

No. Genetic testing does not diagnose mood or mental-health conditions. It provides pathway-level context about reward and dopamine biology that you can discuss with a qualified provider. Diagnosis requires a clinical evaluation. Genetics is one input into understanding yourself, not a substitute for professional care.

Want to see how your reward and dopamine pathways are wired? The Precision Peptide Genetic Test analyzes DRD2 and ANKK1 variants and related markers so you can bring real genetic context to a conversation with your provider.

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

This article is part of the PlexusDx Education Hub. Browse all Brain & Cognitive Health education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.